Theranostics is the combination of two approaches—diagnostics and therapeutics—applied
for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Purpose This review discusses the current state of prostate-specific membrane antigen
(PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC) …

Copper-64 (T1/2= 12.7 h) is a positron and beta-emitting isotope, with decay characteristics
suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer …

225Ac-targeted α-radiotherapy is a promising approach to treating malignancies, including
prostate cancer. However, α-emitting isotopes are difficult to image because of low …

The use of radiopharmaceutical therapies (RPTs) in the treatment of cancers is growing
rapidly, with more agents becoming available for clinical use in last few years and many new …

Simple Summary A significant number of prostate cancer patients will progress to metastatic
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …

There is now an increasing trend for targeting cancers to go beyond early diagnosis and
actually improve Progression-Free Survival and Overall Survival. Identifying patients who …

Abstract Rationale: 225 Ac, a long-lived α-emitter with a half-life of 9.92 days, has garnered
significant attention as a therapeutic radionuclide when coupled with monoclonal antibodies …

Endogenous targeted radiotherapy is emerging as an integral modality to treat a variety of
cancer entities. Nevertheless, despite the positive clinical outcome of the treatment using …